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Multiple myeloma is a malignant proliferation of plasma cells, predominantly involving the bone marrow
and skeletal system. Pleural effusions are rarely associated with multiple myeloma and most often signify
a concurrent disease process, e.g. amyloidosis.1,2 Malignant myelomatous pleural effusions are even more
unusual, occurring in less than 1% of cases of multiple myeloma.1
Here we report the case of a patient with multiple myeloma presenting with a myelomatous pleural
effusion at disease recurrence.
 2011 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Case report
A 66-year old female was diagnosed with multiple myeloma in
June 2009. At diagnosis she had an IgG kappa paraprotein of 95.6 g/L
and bone marrow histology showed 90% inﬁltration with plasma
cells. She completed 8 months of Cyclophosphamide, Thalidomide
and Dexamethasone (CTD) chemotherapy following which her end-
of-treatment bone marrow trephine biopsy showed no detectable
plasma cells and her paraprotein had reduced signiﬁcantly to 6.8 g/L.
She remained in remission until November 2010 when it was noted
that her IgG paraprotein was steadily rising (46.2 g/L). However,
repeat bone marrow trephine biopsy at this time did not show any
evidence of disease recurrence.
In December 2010 the patient presented to hospital with a one
week history of shortness of breath and right sided chest pain.
Chest radiography conﬁrmed a large right sided pleural effusion
(Fig. 1). An intercostal drain was inserted and 2 L of blood-stained
pleural ﬂuid drained. Biochemical analysis of the pleural ﬂuid
conﬁrmed that it was an exudate, (protein 34, LDH 924, glucose
3.4), and further pleural ﬂuid was sent for culture and cytology.
A staging CT, (neck, chest, abdomen and pelvis), performed
following drainage of the pleural ﬂuid, revealed marked right sided
pleural thickening (Fig. 2). Radiologically the CT appearances were
consistent with a mesothelioma. A CT guided pleural biopsy was
performed 10 days later. The patient had become increasingly
dyspnoeic again and her CT images at this time showed marked
progression of the pleural thickening with recurrence of the pleural.
-NC-ND license.effusion. Following the pleural biopsy the patient had an indwelling
tunnelled chest drain inserted allowing her effusion to be drained on
a weekly basis in the community.
Unexpectedly, the histology from the pleural biopsy was
consistent with a pleural plasmacytoma and not a primary pleural
malignancy. Furthermore, the cytology from the pleural ﬂuid
conﬁrmed the presence of plasma cells.
The diagnosis of myelomatous pleural effusion secondary to
a pleural plasmacytomawas made in this patient. This is an unusual
site for disease recurrence in multiple myeloma and was undoubt-
edly the source of this patient’s previously unexplained rising
paraprotein.
The patient was commenced on second-line chemotherapy,
(Cyclophosphamide, Velcade (Bortezomib) and Dexamethasone;
CVD), to which she initially had a good response. The pleural ﬂuid
did not re-accumulate for several weeks and her tunnelled chest
drain was removed. However in March 2011 she returned with
increasing shortness of breath and right-sided pleuritic chest pain.
A CT pulmonary angiogram conﬁrmed the presence of a pulmonary
embolus and demonstrated a marked increase in the right-sided
pleural thickening. The patient was anticoagulated and in view of
her progression on second-line chemotherapy was given high dose
Melphalan with Dexamethasone. The use of Melphalan appears to
have halted the progression of her pleural plasmacytoma at
present, however, it remains to be seenwhether this chemotherapy
regime will be successful in the long term.2. Discussion
The development of pleural effusions in multiple myeloma is
unusual. Kintzer et al. reported the incidence of pleural effusions in
Fig. 1. CXR showing right pleural thickening and pleural effusion.
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effusions presenting in multiple myeloma are seldom a direct
consequence of the myeloma itself, more often the result of
a concurrent disease process or coexisting illness, (e.g. cardiac
failure secondary to amyloidosis, pulmonary embolism, pneumonia
or a secondmalignancy).1,2 Indeed, malignant myelomatous pleural
effusions are rarely observed, occurring in less than 1% of cases.1
Myelomatous pleural effusions may arise from either; extension
of plasmacytomas of the chest wall, invasion from adjacent skeletal
lesions, direct pleural involvement by myeloma (pleural plasma-
cytoma) or following lymphatic obstruction secondary to lymph
node inﬁltration.2e4
The presence of an IgA paraprotein is most commonly associ-
ated with myelomatous pleural effusions, (in up to 80% of cases in
some studies).2,4 The case reported here is unusual in that the
patient had an underlying IgG paraprotein.
The development of myelomatous pleural effusions is frequently
a late complication of the disease and is associated with poorFig. 2. CT chest showing marked pleural thickening of the right hemithorax.prognosis, with previous studies reporting median survival of less
than 4 months.5,6
It is interesting to note that in our case, histological analysis
demonstrated an immature population of plasma cells. This may be
an important contributory factor underlying the development of
myelomatous pleural effusions and may explain the apparent aggre-
ssive nature ofmyelomatous disease that presents in thisway. Indeed
Nonomura et al. discussed the aggressive nature of myeloma asso-
ciated with extramedullary disease, demonstrating rapid disease
progression and treatment resistance.7
The development of extramedullary plasmacytomas (EMPs) in
the context of pre-existing multiple myeloma occurs infrequently
with only 5% of patients with EMPs having coexisting multiple
myeloma.8,9
Pleural involvement in multiple myeloma, as demonstrated in
our case, is all the more unusual.10 In a review of English literature,
only 10 cases have been described previously, (to the best of our
knowledge).9e18
Thalidomide remains the ﬁrst-line treatment for multiple
myeloma in the UK. Although the efﬁcacy of thalidomide in refrac-
tory multiple myeloma has been demonstrated,19 several studies
have reported EMPs to be less responsive to thalidomide,18,20
although more recent studies suggest greater synergistic efﬁcacy
using a combinationof thalidomide anddexamethasone.20 Indeed in
this case, our patient relapsed despite treatment with thalidomide.
Our experience suggests that pleural involvement with myeloma
cells is associated with an aggressive course which is poorly respon-
sive to ﬁrst or second-line therapies used in conventional myeloma
treatment.3. Conclusion
The incidence of myelomatous pleural effusions in multiple
myeloma is rare, often signifying a poor prognostic outlook
following an aggressive natural course. The case discussed here
reinforces that we should not become complacent when investi-
gating pleural effusions in patient’s with a history of multiple
myeloma. Consideration of myelomatous pleural effusions in such
cases will aid rapid diagnosis and initiation of treatment in this
aggressive form of the disease.
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